SPIMACO’s net profit rises 62% to SAR 366 mln in nine-months 2015

19/10/2015 Argaam Exclusive

View other reports

Saudi Pharmaceutical Industries & Medical Appliances Corp. (SPIMACO) reported a net profit of SAR 366.2 million for the first nine months of 2015, a 62.3 percent increase compared to the same period last year mainly attributed to sales growth and the sale of its stake in EirGen Pharma to Opko.

Financials (M)

Item	9m 2014	9m 2015	Change‬
Revenues	1,042.37	1,176.27	12.8 %
Gross Income	534.32	568.12	6.3 %
Operating Income	152.22	164.06	7.8 %
Net Income	225.57	366.17	62.3 %
Average Shares	120.00	120.00	-
EPS (Riyals)	1.88	3.05	62.3 %

The company reported a net income of SAR 29.2 million in Q3 this year, a 20.4 percent decline year-on-year on higher expenses and lower dividends from the company’s investments.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2014	Q3 2015	Change‬
Revenues	266.02	308.27	15.9 %
Gross Income	134.45	131.32	(2.3 %)
Operating Income	31.26	24.69	(21.0 %)
Net Income	36.69	29.16	(20.5 %)
Average Shares	120.00	120.00	-
EPS (Riyals)	0.31	0.24	(20.5 %)

Item	Q2 2015	Q3 2015	Change‬
Revenues	435.80	308.27	(29.3 %)
Gross Income	210.95	131.32	(37.7 %)
Operating Income	48.02	24.69	(48.6 %)
Net Income	237.63	29.16	(87.7 %)
Average Shares	120.00	120.00	-
EPS (Riyals)	1.98	0.24	(87.7 %)

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2006	194.37	17.1 %	91.95	23.6 %	37.75	9.3 %
Q2 2006	185.74	21.6 %	71.43	19.9 %	24.97	22.8 %
Q3 2006	156.57	10.9 %	64.50	9.4 %	23.63	7.4 %
Q4 2006	191.16	1.1 %	80.54	3.1 %	21.73	(13.1 %)
2006	727.84	12.2 %	308.42	13.8 %	108.08	6.1 %
Q1 2007	203.37	4.6 %	91.01	(1.0 %)	40.00	6.0 %
Q2 2007	209.28	12.7 %	66.46	(7.0 %)	3.13	(87.5 %)
Q3 2007	149.40	(4.6 %)	66.84	3.6 %	24.13	2.1 %
Q4 2007	235.70	23.3 %	102.31	27.0 %	30.48	40.3 %
2007	797.75	9.6 %	326.62	5.9 %	97.74	(9.6 %)
Q1 2008	220.58	8.5 %	99.57	9.4 %	41.61	4.0 %
Q2 2008	211.66	1.1 %	74.78	12.5 %	11.06	253.2 %
Q3 2008	145.45	(2.6 %)	74.34	11.2 %	21.36	(11.5 %)
Q4 2008	294.26	24.8 %	114.28	11.7 %	38.48	26.3 %
2008	871.94	9.3 %	362.97	11.1 %	112.51	15.1 %
Q1 2009	257.88	16.9 %	108.57	9.0 %	46.06	10.7 %
Q2 2009	229.00	8.2 %	81.53	9.0 %	16.76	51.6 %
Q3 2009	171.15	17.7 %	72.49	(2.5 %)	18.81	(11.9 %)
Q4 2009	292.71	(0.5 %)	157.00	37.4 %	64.46	67.5 %
2009	950.74	9.0 %	419.59	15.6 %	146.09	29.8 %
Q1 2010	274.33	6.4 %	118.90	9.5 %	52.94	14.9 %
Q2 2010	252.34	10.2 %	100.50	23.3 %	21.50	28.3 %
Q3 2010	191.40	11.8 %	85.88	18.5 %	20.68	9.9 %
Q4 2010	319.57	9.2 %	181.12	15.4 %	70.70	9.7 %
2010	1,037.64	9.1 %	486.40	15.9 %	165.82	13.5 %
Q1 2011	252.08	(8.1 %)	123.51	3.9 %	49.79	(6.0 %)
Q2 2011	292.08	15.7 %	123.61	23.0 %	30.59	42.3 %
Q3 2011	209.24	9.3 %	106.76	24.3 %	33.19	60.5 %
Q4 2011	375.82	17.6 %	206.69	14.1 %	76.86	8.7 %
2011	1,129.22	8.8 %	560.57	15.2 %	191.36	15.4 %
Q1 2012	303.14	20.3 %	153.21	24.0 %	63.10	26.7 %
Q2 2012	286.64	(1.9 %)	140.91	14.0 %	34.78	13.7 %
Q3 2012	227.40	8.7 %	113.28	6.1 %	39.61	19.3 %
Q4 2012	365.97	(2.6 %)	211.16	2.2 %	63.57	(17.3 %)
2012	1,183.15	4.8 %	618.56	10.3 %	201.06	5.1 %
Q1 2013	361.37	19.2 %	184.62	20.5 %	70.64	11.9 %
Q2 2013	344.22	20.1 %	179.12	27.1 %	40.64	16.8 %
Q3 2013	222.91	(2.0 %)	118.64	4.7 %	35.37	(10.7 %)
Q4 2013	382.01	4.4 %	226.14	7.1 %	60.19	(5.3 %)
2013	1,310.50	10.8 %	708.52	14.5 %	205.58	2.2 %
Q1 2014	405.21	12.1 %	206.72	12.0 %	76.05	7.7 %
Q2 2014	371.14	7.8 %	193.14	7.8 %	44.90	10.5 %
Q3 2014	266.02	19.3 %	134.45	13.3 %	31.26	(11.6 %)
Q4 2014	431.06	12.8 %	261.80	15.8 %	90.22	49.9 %
2014	1,470.19	12.2 %	794.54	12.1 %	241.94	17.7 %
Q1 2015	432.20	6.7 %	225.86	9.3 %	91.35	20.1 %
Q2 2015	435.80	17.4 %	210.95	9.2 %	48.02	6.9 %
Q3 2015	308.27	15.9 %	131.32	(2.3 %)	24.69	(21.0 %)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2005	648.90	11.4 %	271.07	26.3 %	101.91	63.7 %
2006	727.84	12.2 %	308.42	13.8 %	108.08	6.1 %
2007	797.75	9.6 %	326.62	5.9 %	97.74	(9.6 %)
2008	871.94	9.3 %	362.97	11.1 %	112.51	15.1 %
2009	950.74	9.0 %	419.59	15.6 %	146.09	29.8 %
2010	1,037.64	9.1 %	486.40	15.9 %	165.82	13.5 %
2011	1,129.22	8.8 %	560.57	15.2 %	191.36	15.4 %
2012	1,183.15	4.8 %	618.56	10.3 %	201.06	5.1 %
2013	1,310.50	10.8 %	708.52	14.5 %	205.58	2.2 %
2014	1,470.19	12.2 %	794.54	12.1 %	241.94	17.7 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2006	37.65	6.4 %	0.37	-	37.65	0.37
Q2 2006	19.13	(21.2 %)	0.19	-	19.13	0.19
Q3 2006	23.80	15.1 %	0.23	-	23.80	0.23
Q4 2006	24.46	54.8 %	0.24	-	24.46	0.24
2006	105.04	9.2 %	1.03	-	105.04	1.03
Q1 2007	39.50	4.9 %	0.39	-	39.50	0.39
Q2 2007	22.57	18.0 %	0.22	-	22.57	0.22
Q3 2007	26.53	11.4 %	0.26	-	26.53	0.26
Q4 2007	33.28	36.1 %	0.33	-	33.28	0.33
2007	121.87	16.0 %	1.20	-	121.87	1.20
Q1 2008	40.93	3.6 %	0.40	-	40.93	0.40
Q2 2008	34.24	51.7 %	0.34	(0.45)	34.70	0.34
Q3 2008	15.62	(41.1 %)	0.15	(3.69)	19.83	0.20
Q4 2008	37.48	12.6 %	0.37	-	37.48	0.37
2008	128.27	5.2 %	1.26	(3.89)	132.16	1.30
Q1 2009	42.69	4.3 %	0.42	(0.18)	42.87	0.42
Q2 2009	37.81	10.4 %	0.37	0.00	37.81	0.37
Q3 2009	15.84	1.4 %	0.16	0.00	15.84	0.16
Q4 2009	58.48	56.0 %	0.58	(3.12)	61.60	0.61
2009	154.81	20.7 %	1.53	(3.30)	158.11	1.56
Q1 2010	45.32	6.2 %	0.38	(3.24)	48.56	0.40
Q2 2010	43.09	14.0 %	0.36	-	43.09	0.36
Q3 2010	18.07	14.1 %	0.15	-	18.07	0.15
Q4 2010	70.04	19.8 %	0.58	-	70.04	0.58
2010	176.52	14.0 %	1.47	(3.24)	179.76	1.50
Q1 2011	45.71	0.9 %	0.38	-	45.71	0.38
Q2 2011	60.75	41.0 %	0.51	-	60.75	0.51
Q3 2011	29.75	64.6 %	0.25	-	29.75	0.25
Q4 2011	74.06	5.7 %	0.62	-	74.06	0.62
2011	211.44	19.8 %	1.76	-	211.44	1.76
Q1 2012	56.45	23.5 %	0.47	-	56.45	0.47
Q2 2012	90.14	48.4 %	0.75	-	90.14	0.75
Q3 2012	32.33	8.7 %	0.27	-	32.33	0.27
Q4 2012	53.73	(27.5 %)	0.45	-	53.73	0.45
2012	232.65	10.0 %	1.94	-	232.65	1.94
Q1 2013	63.15	11.9 %	0.53	-	63.15	0.53
Q2 2013	113.71	26.1 %	0.95	-	113.71	0.95
Q3 2013	34.19	5.8 %	0.28	-	34.19	0.28
Q4 2013	57.01	6.1 %	0.48	-	57.01	0.48
2013	266.82	14.7 %	2.22	-	266.82	2.22
Q1 2014	91.17	44.4 %	0.76	-	91.17	0.76
Q2 2014	97.72	(14.1 %)	0.81	-	97.72	0.81
Q3 2014	36.69	7.3 %	0.31	-	36.69	0.31
Q4 2014	91.29	60.1 %	0.76	-	91.29	0.76
2014	316.85	18.8 %	2.64	-	316.85	2.64
Q1 2015	99.39	9.0 %	0.83	-	99.39	0.83
Q2 2015	237.63	143.2 %	1.98	151.31	86.32	0.72
Q3 2015	29.16	(20.5 %)	0.24	-	29.16	0.24

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2005	96.15	46.8 %	0.95	-	96.15	0.95
2006	105.04	9.2 %	1.03	-	105.04	1.03
2007	121.87	16.0 %	1.20	-	121.87	1.20
2008	128.27	5.2 %	1.26	(3.89)	132.16	1.30
2009	154.81	20.7 %	1.53	(3.30)	158.11	1.56
2010	176.52	14.0 %	1.47	(3.24)	179.76	1.50
2011	211.44	19.8 %	1.76	-	211.44	1.76
2012	232.65	10.0 %	1.94	-	232.65	1.94
2013	266.82	14.7 %	2.22	-	266.82	2.22
2014	316.85	18.8 %	2.64	-	316.85	2.64

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2006	42.61 %	18.61 %	14.53 %
Q2 2006	42.30 %	18.33 %	13.13 %
Q3 2006	42.16 %	18.23 %	13.28 %
Q4 2006	42.37 %	17.65 %	14.43 %
2006	42.37 %	17.65 %	14.43 %
Q1 2007	41.73 %	17.98 %	14.51 %
Q2 2007	39.78 %	14.82 %	14.51 %
Q3 2007	40.47 %	15.48 %	15.01 %
Q4 2007	40.94 %	15.79 %	15.28 %
2007	40.94 %	15.79 %	15.28 %
Q1 2008	41.13 %	15.70 %	15.13 %
Q2 2008	42.03 %	16.67 %	16.57 %
Q3 2008	43.15 %	16.47 %	15.83 %
Q4 2008	41.63 %	16.30 %	15.25 %
2008	41.63 %	16.30 %	15.16 %
Q1 2009	40.91 %	16.13 %	14.83 %
Q2 2009	40.87 %	16.44 %	14.89 %
Q3 2009	39.57 %	15.73 %	14.07 %
Q4 2009	44.13 %	18.49 %	16.63 %
2009	44.13 %	18.49 %	16.63 %
Q1 2010	44.45 %	18.88 %	16.94 %
Q2 2010	45.32 %	18.93 %	17.07 %
Q3 2010	45.73 %	18.73 %	16.95 %
Q4 2010	46.88 %	18.85 %	17.32 %
2010	46.88 %	18.85 %	17.32 %
Q1 2011	48.36 %	18.99 %	17.42 %
Q2 2011	48.73 %	19.12 %	18.44 %
Q3 2011	49.86 %	19.99 %	19.22 %
Q4 2011	49.64 %	19.57 %	18.62 %
2011	49.64 %	19.65 %	18.72 %
Q1 2012	50.01 %	19.86 %	18.73 %
Q2 2012	51.72 %	20.36 %	21.31 %
Q3 2012	51.47 %	20.54 %	21.21 %
Q4 2012	52.28 %	19.56 %	19.66 %
2012	52.28 %	19.56 %	19.66 %
Q1 2013	52.36 %	19.26 %	19.28 %
Q2 2013	52.98 %	18.87 %	20.24 %
Q3 2013	53.58 %	18.66 %	20.45 %
Q4 2013	54.06 %	18.26 %	20.45 %
2013	54.06 %	18.16 %	20.36 %
Q1 2014	53.95 %	17.92 %	21.86 %
Q2 2014	53.91 %	17.74 %	20.28 %
Q3 2014	53.39 %	16.79 %	19.84 %
Q4 2014	54.03 %	18.15 %	21.50 %
2014	54.04 %	18.15 %	21.55 %
Q1 2015	54.34 %	18.90 %	21.67 %
Q2 2015	53.23 %	18.31 %	20.04 %
Q3 2015	51.63 %	17.40 %	19.05 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2005	41.77 %	18.97 %	14.82 %
2006	42.37 %	17.65 %	14.43 %
2007	40.94 %	15.79 %	15.28 %
2008	41.63 %	16.30 %	15.16 %
2009	44.13 %	18.49 %	16.63 %
2010	46.88 %	18.85 %	17.32 %
2011	49.64 %	19.65 %	18.72 %
2012	52.28 %	19.56 %	19.66 %
2013	54.06 %	18.16 %	20.36 %
2014	54.04 %	18.15 %	21.55 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2006	47.31 %	22.09 %	19.37 %
Q2 2006	38.46 %	16.07 %	10.30 %
Q3 2006	41.20 %	17.41 %	15.20 %
Q4 2006	42.13 %	14.88 %	12.80 %
Q1 2007	44.75 %	23.06 %	19.42 %
Q2 2007	31.76 %	4.83 %	10.79 %
Q3 2007	44.74 %	20.85 %	17.75 %
Q4 2007	43.41 %	16.03 %	14.12 %
Q1 2008	45.14 %	22.16 %	18.55 %
Q2 2008	35.33 %	8.71 %	16.39 %
Q3 2008	51.11 %	19.82 %	13.64 %
Q4 2008	38.84 %	15.63 %	12.74 %
Q1 2009	42.10 %	20.70 %	16.62 %
Q2 2009	35.60 %	10.54 %	16.51 %
Q3 2009	42.35 %	15.37 %	9.25 %
Q4 2009	53.64 %	24.60 %	21.04 %
Q1 2010	43.34 %	21.92 %	17.70 %
Q2 2010	39.83 %	11.52 %	17.08 %
Q3 2010	44.87 %	14.68 %	9.44 %
Q4 2010	56.68 %	24.50 %	21.92 %
Q1 2011	49.00 %	22.74 %	18.13 %
Q2 2011	42.32 %	13.00 %	20.80 %
Q3 2011	51.02 %	19.57 %	14.22 %
Q4 2011	55.00 %	22.56 %	19.71 %
Q1 2012	50.54 %	23.32 %	18.62 %
Q2 2012	49.16 %	14.95 %	31.45 %
Q3 2012	49.82 %	20.53 %	14.22 %
Q4 2012	57.70 %	19.47 %	14.68 %
Q1 2013	51.09 %	21.68 %	17.48 %
Q2 2013	52.04 %	14.20 %	33.03 %
Q3 2013	53.22 %	19.34 %	15.34 %
Q4 2013	59.20 %	18.05 %	14.92 %
Q1 2014	51.02 %	20.19 %	22.50 %
Q2 2014	52.04 %	13.80 %	26.33 %
Q3 2014	50.54 %	13.97 %	13.79 %
Q4 2014	60.73 %	22.54 %	21.18 %
Q1 2015	52.26 %	22.70 %	23.00 %
Q2 2015	48.40 %	12.42 %	19.81 %
Q3 2015	42.60 %	9.85 %	9.46 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2006	101.51	0.97	0.97	25.43
Q2 2006	101.51	0.92	0.92	21.37
Q3 2006	101.51	0.95	0.95	27.26
Q4 2006	101.51	1.03	1.03	19.65
Q1 2007	101.51	1.05	1.05	19.84
Q2 2007	101.51	1.09	1.09	19.42
Q3 2007	101.51	1.11	1.11	21.04
Q4 2007	101.51	1.20	1.20	28.41
Q1 2008	101.51	1.21	1.21	26.83
Q2 2008	101.51	1.33	1.33	27.74
Q3 2008	101.51	1.22	1.27	21.88
Q4 2008	101.51	1.26	1.31	13.76
Q1 2009	101.51	1.28	1.33	14.17
Q2 2009	101.51	1.32	1.36	17.62
Q3 2009	101.51	1.32	1.32	19.72
Q4 2009	101.51	1.53	1.56	21.46
Q1 2010	120.00	1.31	1.36	22.04
Q2 2010	120.00	1.36	1.41	19.98
Q3 2010	120.00	1.37	1.43	21.69
Q4 2010	120.00	1.47	1.50	24.48
Q1 2011	120.00	1.47	1.47	25.41
Q2 2011	120.00	1.62	1.62	27.29
Q3 2011	120.00	1.72	1.72	25.92
Q4 2011	120.00	1.75	1.75	26.50
Q1 2012	120.00	1.84	1.84	30.26
Q2 2012	120.00	2.09	2.09	25.75
Q3 2012	120.00	2.11	2.11	26.24
Q4 2012	120.00	1.94	1.94	25.28
Q1 2013	120.00	1.99	1.99	27.18
Q2 2013	120.00	2.19	2.19	26.14
Q3 2013	120.00	2.21	2.21	27.35
Q4 2013	120.00	2.23	2.23	32.18
Q1 2014	120.00	2.47	2.47	32.96
Q2 2014	120.00	2.33	2.33	33.21
Q3 2014	120.00	2.35	2.35	35.74
Q4 2014	120.00	2.64	2.64	28.75
Q1 2015	120.00	2.71	2.71	27.84
Q2 2015	120.00	3.87	2.61	28.72
Q3 2015	120.00	3.81	2.55	24.87

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2005	101.51	0.95	0.95	20.18
2006	101.51	1.03	1.03	19.65
2007	101.51	1.20	1.20	28.41
2008	101.51	1.26	1.30	13.76
2009	101.51	1.53	1.56	21.46
2010	120.00	1.47	1.50	24.48
2011	120.00	1.76	1.76	26.50
2012	120.00	1.94	1.94	25.28
2013	120.00	2.22	2.22	32.18
2014	120.00	2.64	2.64	28.75

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2006	More than 100	More than 100	4.07
Q2 2006	97.11	97.11	4.18
Q3 2006	89.06	89.06	3.10
Q4 2006	33.13	33.13	1.74
Q1 2007	30.19	30.19	1.60
Q2 2007	28.33	28.33	1.59
Q3 2007	28.70	28.70	1.52
Q4 2007	33.83	33.83	1.43
Q1 2008	27.68	27.68	1.25
Q2 2008	26.79	26.70	1.28
Q3 2008	20.49	19.74	1.14
Q4 2008	12.99	12.53	1.19
Q1 2009	14.92	14.39	1.35
Q2 2009	17.20	16.65	1.28
Q3 2009	18.29	18.26	1.22
Q4 2009	15.25	14.94	1.08
Q1 2010	16.69	16.04	0.99
Q2 2010	14.70	14.15	1.00
Q3 2010	14.64	14.10	0.93
Q4 2010	15.82	15.53	0.95
Q1 2011	17.65	17.65	1.02
Q2 2011	15.68	15.68	0.93
Q3 2011	14.41	14.41	0.96
Q4 2011	15.03	15.03	0.99
Q1 2012	17.92	17.92	1.09
Q2 2012	12.56	12.56	1.02
Q3 2012	13.70	13.70	1.10
Q4 2012	14.74	14.74	1.13
Q1 2013	13.60	13.60	1.00
Q2 2013	15.51	15.51	1.30
Q3 2013	15.70	15.70	1.27
Q4 2013	19.02	19.02	1.32
Q1 2014	19.07	19.07	1.43
Q2 2014	19.29	19.29	1.36
Q3 2014	21.41	21.41	1.41
Q4 2014	12.89	12.89	1.18
Q1 2015	14.78	14.78	1.44
Q2 2015	11.59	17.18	1.56
Q3 2015	9.46	14.14	1.45

Period	P/E	Adjusted P/E	Price/book
2005	More than 100	More than 100	6.89
2006	33.13	33.13	1.74
2007	33.83	33.83	1.43
2008	12.99	12.60	1.19
2009	15.25	14.94	1.08
2010	15.82	15.53	0.95
2011	14.95	14.95	0.99
2012	14.74	14.74	1.13
2013	19.11	19.11	1.32
2014	12.89	12.89	1.18

Business Segments (Million)

Compared With The

Period	Medical & Pharmaceutical production segment	Investment activity
Q1 2006	194.37	-
Q2 2006	185.74	-
Q3 2006	156.57	-
Q4 2006	191.16	-
Q1 2007	203.37	-
Q2 2007	209.28	-
Q3 2007	149.40	-
Q4 2007	235.69	-
Q1 2008	220.58	-
Q2 2008	211.66	-
Q3 2008	145.45	-
Q4 2008	294.25	-
Q1 2009	257.88	-
Q2 2009	229.00	-
Q3 2009	171.15	-
Q4 2009	292.71	-
Q1 2010	274.33	-
Q2 2010	252.34	-
Q3 2010	191.41	-
Q4 2010	319.57	-
Q1 2011	252.08	-
Q2 2011	292.08	-
Q3 2011	209.24	-
Q4 2011	375.82	-
Q1 2012	303.14	-
Q2 2012	286.65	-
Q3 2012	227.40	-
Q4 2012	365.97	-
Q1 2013	361.37	-
Q2 2013	344.22	-
Q3 2013	222.91	-
Q4 2013	382.01	-
Q1 2014	405.21	-
Q2 2014	374.14	-
Q3 2014	266.02	-
Q4 2014	427.82	-
Q1 2015	432.29	14.84
Q2 2015	436.99	195.93
Q3 2015	308.38	9.55

Period	Medical & Pharmaceutical production segment	Investment activity
2005	648.90	-
2006	727.84	-
2007	797.75	-
2008	871.94	-
2009	950.74	-
2010	1,037.64	-
2011	1,129.22	-
2012	1,183.15	-
2013	1,310.50	-
2014	1,470.19	-

Analysts Estimates (Million)

Item	Q3 2015 (e)	Q3 2015 (a)	Change‬
Average	51.00	29.16	(42.8 %)

Estimates vs Actual (Million)

Item	Q3 2015 (e)	Q3 2015 (a)	Change
99Hlala Capital	51.00	29.16	(42.8) %

Financial Ratios

	Current
Market Cap (M Riyal)	3,732.00
Enterprise Value (EV) (M)	5,001.60
Shares Outstanding ((M))	120.00
EPS ( Riyal) (TTM)	0.10
Book Value (BV) ( Riyal)	12.27
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	More than 100
P/E (TTM)	More than 100
Price/book	2.53
Return on Average Assets (%) (TTM)	0.3
Return on Average Equity (%) (TTM)	0.8

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

SPIMACO’s net profit rises 62% to SAR 366 mln in nine-months 2015

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2015 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

SPIMACO’s net profit rises 62% to SAR 366 mln in nine-months 2015

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q3 2015

Revenue by Business Segment (Latest) 2015 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Saudi Pharmaceutical Industries and Medical Appliances Corp. (SPIMACO)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)